CCLD Quote, Financials, Valuation and Earnings

Astrana Health has a net margin of 7.05% compared to CareCloud's net margin of 1.08%. CareCloud's return on equity of 21.35% beat Astrana Health's return on equity of 7.09%.

CareCloud has a consensus price target of $4.42, signalling upside risk potential of 117.57%. On the other hand Astrana Health has an analysts' consensus of $50.3000 which suggests that it could grow by 99.68%. Given that CareCloud has higher upside potential than Astrana Health, analysts believe CareCloud is more attractive than Astrana Health.

CareCloud has a beta of 2.047, which suggesting that the stock is 104.714% more volatile than S&P 500. In comparison Astrana Health has a beta of 0.998, suggesting its less volatile than the S&P 500 by 0.209%.

CareCloud has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CareCloud pays -- of its earnings as a dividend. Astrana Health pays out 9.35% of its earnings as a dividend. Astrana Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CareCloud quarterly revenues are $27.6M, which are smaller than Astrana Health quarterly revenues of $620.4M. CareCloud's net income of $1.9M is lower than Astrana Health's net income of $6.7M. Notably, CareCloud's price-to-earnings ratio is -- while Astrana Health's PE ratio is 34.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CareCloud is 0.33x versus 0.54x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.

Biote has a net margin of 7.05% compared to CareCloud's net margin of 28%. CareCloud's return on equity of 21.35% beat Biote's return on equity of --.

CareCloud has a consensus price target of $4.42, signalling upside risk potential of 117.57%. On the other hand Biote has an analysts' consensus of $7.00 which suggests that it could grow by 72.22%. Given that CareCloud has higher upside potential than Biote, analysts believe CareCloud is more attractive than Biote.

CareCloud has a beta of 2.047, which suggesting that the stock is 104.714% more volatile than S&P 500. In comparison Biote has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

CareCloud has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biote offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CareCloud pays -- of its earnings as a dividend. Biote pays out 150.27% of its earnings as a dividend.

CareCloud quarterly revenues are $27.6M, which are smaller than Biote quarterly revenues of $49M. CareCloud's net income of $1.9M is lower than Biote's net income of $13.7M. Notably, CareCloud's price-to-earnings ratio is -- while Biote's PE ratio is 6.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CareCloud is 0.33x versus 0.68x for Biote. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of 7.05% compared to CareCloud's net margin of 3.55%. CareCloud's return on equity of 21.35% beat Cryo-Cell International's return on equity of --.

CareCloud has a consensus price target of $4.42, signalling upside risk potential of 117.57%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 75.26%. Given that CareCloud has higher upside potential than Cryo-Cell International, analysts believe CareCloud is more attractive than Cryo-Cell International.

CareCloud has a beta of 2.047, which suggesting that the stock is 104.714% more volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.595%.

CareCloud has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 13.4% to investors and pays a quarterly dividend of $0.15 per share. CareCloud pays -- of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend.

CareCloud quarterly revenues are $27.6M, which are larger than Cryo-Cell International quarterly revenues of $8M. CareCloud's net income of $1.9M is higher than Cryo-Cell International's net income of $282.9K. Notably, CareCloud's price-to-earnings ratio is -- while Cryo-Cell International's PE ratio is 485.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CareCloud is 0.33x versus 1.24x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners has a net margin of 7.05% compared to CareCloud's net margin of -5.49%. CareCloud's return on equity of 21.35% beat P3 Health Partners's return on equity of -53.56%.

CareCloud has a consensus price target of $4.42, signalling upside risk potential of 117.57%. On the other hand P3 Health Partners has an analysts' consensus of $16.25 which suggests that it could grow by 102.11%. Given that CareCloud has higher upside potential than P3 Health Partners, analysts believe CareCloud is more attractive than P3 Health Partners.

CareCloud has a beta of 2.047, which suggesting that the stock is 104.714% more volatile than S&P 500. In comparison P3 Health Partners has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

CareCloud has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CareCloud pays -- of its earnings as a dividend. P3 Health Partners pays out -- of its earnings as a dividend.

CareCloud quarterly revenues are $27.6M, which are smaller than P3 Health Partners quarterly revenues of $373.2M. CareCloud's net income of $1.9M is higher than P3 Health Partners's net income of -$20.5M. Notably, CareCloud's price-to-earnings ratio is -- while P3 Health Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CareCloud is 0.33x versus 0.02x for P3 Health Partners. Usually stocks with elevated PS ratios are considered overvalued.